Furthermore, treatment with APCP (days 0–6) in a humanised mouse model of GVHD, which does not involve pre-conditioning, resulted in worsened disease with increased weight loss, liver apoptosis and serum human IL-2 [113]. This evidence concerns the gene IL2 and graft versus host disease.